There are current clinical trials in PCa patients using different monotherapies or therapies combined with ADT to induce TAMs re-education such as CSF-1R inhibitor (JNJ-40346527) (NCT03177460) [31], CXCR2 inhibitor (AZD5069) (NCT03177187) [24] and several trials using GM-CSF based combinations (NCT03600350, NCT03579654, NCT02961257, NCT03686683) [32–35]. The gene discussed is CSF2; the disease is posterior cortical atrophy.